|Description||LY 235959 is a competitive N-Methyl-D-Aspartate Receptor antagonist originated by Eli Lilly. No development was reported for treatment of Movement disorders in USA . Research for treatment of Alzheimer's disease was discontinued.|
|Synonyms||(3S)-(3-alpha-4-alpha,alpha-6-beta-8-alpha,alpha)-Decahydro-6-(phosphonomethyl)-3-isoquinolinecarboxylic acid;LY 235959|
|Solubility||Soluble in DMSO|
|Application||Alzheimer's disease;Movement disorders|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator Eli Lilly|
LY 233536 is a novel competitive N-methyl-D-aspartate (NMDA) receptor antagonist, but few detailed information has been published yet.
(-)-MK 801 Maleate
MK-801 is a potent, selective and non-competitive NMDA receptor antagonist with Kd of 37.2 nM in rat brain membranes.
L-701,324 is a selective antagonist at the glycine site of the NMDA glutamate receptor. L-701,324 shows a beneficial action in the animal model of parkinsonian ...
LY 257883, also known as PPPA, is a competitive NMDA receptor antagonist which displays moderate selectivity for NR2A-containing receptors. Ki values are 0.13μM...
(-)-MK-801 maleate is a potent, selective and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with Ki of 30.5 nM that acts at the NMDA receptor-...
Ifenprodil is an atypical noncompetitive antagonist at the NMDA receptor, it interacts with high affinity at a homogeneous population of NMDA receptors in neona...
Amantadine is can be used as an antiviral and an antiparkinsonian drug. It is a NMDA receptor antagonist. Amantadine is also a useful building block in organic ...
Cgp 39653 is a competitive N-Methyl-D-aspartate (NMDA) receptor antagonist. CGP 39653 can selectively bins to the NMDA receptor as an antagonist with high affin...
Besonprodil, a benzimidazolone bioisostere, is an NMDA antagonist that selective for the NR2B subunit.
CGP 43487 has been found to be a NMDA receptor antagonist and was once studied about its influenment of dopaminergic function as a supplement in the treatment o...
Dioxadrol hydrochloride has been found to be an NMDA antagonist and is used as a dissociative anaesthetic drug. It produces similar effects to PCP in animals. I...
D-AP7 is a selective NMDA receptor antagonist that inhibits the glutamate binding site and activation of NMDA receptor. It is the 8-Bromo-cGMP and the more acti...
PEAQX(NVP-AAM 077) is a potent and orally active NMDA antagonist with a 15-fold preference for human NMDA receptors with the 1A/2A(IC50=270 nM), rather than 1A/...
GV-196771, an indole derivative, has been found to be a non-opioid analgesic agent which is also a NMDA antagonist binds to glycine-binding site and was once st...
CP-283097 is NR2B N-Methyl-D-Aspartate receptor antagonist originated by Pfizer. Preclinical trials for the treatment of Migraine and Neurodegenerative disorder...
Rapastinel, a brain penetrable tetrapeptide, could be a partial agonist of NMDA receptor. It was already finished the Phase II trial for acting as an antidepres...
The hydrate of Felbamate which is an effective anticonvulsant agent. It was found to be clinically active for probably restraining the effectivity of NMDA.
AM-36 is a potent blocker of batrachotoxinin (BTX)-sensitive Na+ channel binding in rat brain homogenates with an IC50 of 0.28 microM. As a unique neuroprotecti...
Apimostinel is a selective partial agonist of an allosteric site of the glycine site of the NMDA receptor complex under investigation by Naurex. Its mechanism o...